What is HC Wainwright's Forecast for CRVS Q3 Earnings?

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share estimate for Corvus Pharmaceuticals to ($0.14), a slight improvement from the previous estimate of ($0.15).
• Corvus Pharmaceuticals' stock received various ratings recently, with Mizuho setting a price target of $11.00 and Oppenheimer raising its target to $17.00, indicating a positive market outlook.
• Corvus Pharmaceuticals experienced a recent stock price increase of 11.1%, with shares currently trading at $5.00, while it has a market cap of approximately $372.55 million.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings per share estimates for shares of Corvus Pharmaceuticals in a research note issued to investors on Monday, August 11th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.15). The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Corvus Pharmaceuticals' Q4 2025 earnings at ($0.14) EPS, FY2025 earnings at ($0.51) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.50) EPS and FY2027 earnings at ($0.40) EPS.

Several other equities research analysts also recently issued reports on the company. Mizuho set a $11.00 price objective on Corvus Pharmaceuticals and gave the stock an "outperform" rating in a research note on Tuesday, May 20th. Oppenheimer reaffirmed an "outperform" rating and set a $17.00 price target (up from $15.00) on shares of Corvus Pharmaceuticals in a research note on Friday, May 9th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Corvus Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $15.00.

Corvus Pharmaceuticals Trading Up 11.1%

Shares of Corvus Pharmaceuticals stock opened at $5.00 on Thursday. The stock has a 50-day moving average price of $4.21 and a 200 day moving average price of $4.05. The company has a market cap of $372.55 million, a P/E ratio of -4.95 and a beta of 0.42. Corvus Pharmaceuticals has a 1 year low of $2.54 and a 1 year high of $10.00.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.03.

Insider Buying and Selling at Corvus Pharmaceuticals

In other news, Director Peter A. Thompson sold 1,176,332 shares of the firm's stock in a transaction dated Friday, June 27th. The stock was sold at an average price of $4.16, for a total transaction of $4,893,541.12. Following the completion of the sale, the director directly owned 7,165,006 shares of the company's stock, valued at $29,806,424.96. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 28.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in CRVS. Sowell Financial Services LLC acquired a new position in shares of Corvus Pharmaceuticals during the 1st quarter valued at about $38,000. Virtus ETF Advisers LLC acquired a new position in shares of Corvus Pharmaceuticals during the 4th quarter valued at about $47,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $49,000. ProShare Advisors LLC acquired a new stake in Corvus Pharmaceuticals in the 2nd quarter valued at approximately $54,000. Finally, Alpine Global Management LLC acquired a new stake in Corvus Pharmaceuticals in the 4th quarter valued at approximately $62,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.